USE OF PRESCRIPTION INFORMATION Sample Clauses

USE OF PRESCRIPTION INFORMATION. Subject to the provisions of Section 6 regarding AdvancePCS' proprietary rights, each party shall be entitled to use the information provided to AdvancePCS by Network Providers and Members in connection with Claims ("CLAIMS INFORMATION") in any manner such party deems appropriate; provided, however, that each party shall maintain the confidentiality of such information (including the identity of any Member) to the extent required by applicable Law, and shall refrain from any use of such information for improper employment or other purposes. Each party shall be solely responsible for its own use of the Claims Information, and shall indemnify and hold harmless the other party for, from and against any and all costs, losses and damages incurred by such other party as a result of such use.
AutoNDA by SimpleDocs

Related to USE OF PRESCRIPTION INFORMATION

  • Option Information (a) Date of Option: September 12, 2008

  • Use of Confidential Information The parties agree that during the term of this Agreement and thereafter, Confidential Information is to be used solely in connection with satisfying their obligations pursuant to this Agreement, and that a party shall neither disclose Confidential Information to any third party, nor use Confidential Information for its own benefit, except as may be necessary to perform its obligations pursuant to this Agreement or as expressly authorized in writing by the other party, as the case may be. Neither party shall disclose any Confidential Information to any other persons or entities, except on a “need to know” basis and then only: (i) to their own employees and Agents (as defined below); (ii) to their own accountants and legal representatives, provided that any such representatives shall be subject to subsection(iv) below; (iii) to their own affiliates, provided that such affiliates shall be restricted in use and redisclosure of the Confidential Information to the same extent as the parties hereto. “Agents”, for purposes of this Section, mean each of the parties’ advisors, directors, officers, employees, contractors, consultants affiliated entities (i.e., an entity controlling, controlled by, or under common control with a party), or other agents. If and to the extent any Agent of the recipient receive Confidential Information, such recipient party shall be responsible for such Agent’s full compliance with the terms and conditions of this Agreement and shall be liable for any such Agent’s non-compliance.

  • Maintenance of Confidential Information The Contractor acknowledges that in the course of its appointment hereunder the Contractor will, either directly or indirectly, have access to and be entrusted with information (whether oral, written or by inspection) relating to the Company or its respective affiliates, associates or customers (the “Confidential Information”). For the purposes of this Agreement, “Confidential Information” includes, without limitation, any and all Developments (as defined herein), trade secrets, inventions, innovations, techniques, processes, formulas, drawings, designs, products, systems, creations, improvements, documentation, data, specifications, technical reports, customer lists, supplier lists, distributor lists, distribution channels and methods, retailer lists, reseller lists, employee information, financial information, sales or marketing plans, competitive analysis reports and any other thing or information whatsoever, whether copyrightable or uncopyrightable or patentable or unpatentable. The Contractor acknowledges that the Confidential Information constitutes a proprietary right, which the Company is entitled to protect. Accordingly the Contractor covenants and agrees that during the Term and thereafter until such time as all the Confidential Information becomes publicly known and made generally available through no action or inaction of the Contractor, the Contractor will keep in strict confidence the Confidential Information and shall not, without prior written consent of the Company in each instance, disclose, use or otherwise disseminate the Confidential Information, directly or indirectly, to any third party.

  • Company Creation and Use of Confidential Information The Executive understands and acknowledges that the Company has invested, and continues to invest, substantial time, money and specialized knowledge into developing its resources, creating a customer base, generating customer and potential customer lists, training its employees, and improving its product offerings in the field of financial services. The Executive understands and acknowledges that as a result of these efforts, the Company has created, and continues to use and create Confidential Information. This Confidential Information provides the Company with a competitive advantage over others in the marketplace.

  • Use of Proprietary Information Officer recognizes that Corporation possesses a proprietary interest in all of the information described in Section 6 and has the exclusive right and privilege to use, protect by copyright, patent or trademark, manufacture or otherwise exploit the processes, ideas and concepts described therein to the exclusion of Officer, except as otherwise agreed between Corporation and Officer in writing. Officer expressly agrees that any products, inventions, discoveries or improvements made by Officer, his agents or affiliates based on or arising out of the information described in Section 6 shall be (i) deemed a work made for hire under the terms of United States Copyright Act, 17 U.S.C. § 101 et seq., and Corporation shall be the owner of all such rights with respect thereto and (ii) the property of and inure to the exclusive benefit of Corporation.

  • Treatment of Confidential Information (A) Each party agrees that at all times during and after the terms of this Agreement, it shall use, handle, collect, maintain, and safeguard Confidential Information in accordance with (1) the confidentiality and non-disclosure requirements of this Agreement; (2) the GLB Act, as applicable and as it may be amended; and (3) such other Applicable Law, whether in effect now or in the future.

  • Information Updates During the term of this Agreement the Trust shall have the ongoing obligation to provide UMBFS with the following documents as soon as they become effective: (i) certified copies of all amendments to its Declaration of Trust and By-laws made after the date of this Agreement; and (ii) a copy of each Fund’s currently effective Prospectus. For purposes of this Agreement, UMBFS shall not be deemed to have notice of any information contained in any such Prospectus until a reasonable time after it is actually received by UMBFS.

  • Contact Information Following are the Mxxxxx Sxxxxxx departments involved in servicing the Funds and the corresponding contact information. Abbreviation Department Primary Contact Telephone E-mail Futures Desk MSC Futures Trading Desk Bxxxx Xxxxxxx Dxxxxx Xxxxxxxxx 212.761.1782 212.761.2248 Bxxxx.Xxxxxxx@xxxxxxxxxxxxx.xxx Dxxxxx.Xxxxxxxxx@xxxxxxxxxxxxx.xxx Futures Ops MSC Futures Operations Sxxxx Xxxxxxx Exxx Xxxxx 212.276.0477 212.276.0578 Sxxxx.Xxxxxxx@xxxxxxxxxxxxx.xxx Exxx.Xxxxx@xxxxxxxxxxxxx.xxx FX Desk MSC Foreign Exchange Trading Desk Mxxxxxx Xxxxxxx 212.761.2700 Mxxxxxx.Xxxxxxx@xxxxxxxxxxxxx.xxx FX Ops MSC Foreign Exchange Operations Jxxx Xxxxx 718.754.4868 Jxxx.Xxxxx@xxxxxxxxxxxxx.xxx MF Accounting Mxxxxx Sxxxxxx Managed Futures Accounting Jxx Xxxxxxxx Kxxxx Xxxxxx 917.790.5702 917.790.5701 Jxx.Xxxxxxxx@xxxxxxxxxxxxx.xxx Kxxxx.Xxxxxx@xxxxxxxxxxxxx.xxx MF Ops Mxxxxx Sxxxxxx Managed Futures Operations Lxxxx Xxxxx 212.905.2720 Lxxxx.Xxxxxxxxx@xxxxxxxxxxxx.xxx MF Prod Org Mxxxxx Sxxxxxx Managed Futures Product Origination Pxxxxxx Xxxx 212.905.2736 Pxxxxxx.Xxxx@xxxxxxxxxxxxx.xxx MF Strat Plan Mxxxxx Sxxxxxx Managed Futures Strategic Planning Cxxxx Xxxxx 212.905.2731 Cxxxx.Xxxxx@xxxxxxxxxxxxx.xxx FUND ACCOUNTS: Account Configuration · Futures and Futures Options Trading - For each CTA trading program three Fund trading accounts will be assigned. A MS&Co segregated account, prefix 052. A MS&Co secured account, prefix 05A. A MSIL non-regulated (by the CFTC) account, prefix 045. · FX (Non-Options) Trading - One Fund account for each CTA trading program will be assigned at MS&Co, prefix 058. · FX Options Trading – One Fund account for each CTA trading program will be assigned at MSCG (if needed), prefix 057. · Excess and FX Custody Accounts – For each CTA trading program two Fund accounts will be set up at MS&Co. One account will be designated as a custody account for MS&Co FX. MF Ops will maintain equity in the custody account sufficient to cover margin requirements of the FX trading account. The second account will contain the balance of excess equity that is not required in the custody and futures trading accounts. Statements · Futures – The CTA should contact Futures Ops regarding access to Fund futures account statements. · FX – The CTA should contact FX Ops regarding access to Fund FX account statements. · Excess and Custody – The CTA should contact MF Ops regarding access to the Fund account statements at MS&Co.

  • Information The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be, furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Securities which have been requested by the Buyer or its advisors. The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be, afforded the opportunity to ask questions of the Company. Notwithstanding the foregoing, the Company has not disclosed to the Buyer any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior to or promptly following such disclosure to the Buyer. Neither such inquiries nor any other due diligence investigation conducted by Buyer or any of its advisors or representatives shall modify, amend or affect Buyer’s right to rely on the Company’s representations and warranties contained in Section 3 below. The Buyer understands that its investment in the Securities involves a significant degree of risk. The Buyer is not aware of any facts that may constitute a breach of any of the Company's representations and warranties made herein.

  • Director Notification Information If you are a director of a Singapore Subsidiary, you may need to notify the Singapore Subsidiary in writing within two business days of your receiving an interest (e.g., Performance Units) in the Company or any Subsidiary or within two business days of you becoming a director if such an interest exists at the time. This notification requirement also applies to an associate director of the Singapore Subsidiary and to a shadow director of the Singapore Subsidiary (i.e., an individual who is not on the board of directors of the Singapore Subsidiary but who has sufficient control so that the board of directors of the Singapore Subsidiary acts in accordance with the “directions and instructions” of the individual). US/INTERNATIONAL EMPLOYEE (EXHIBIT B) SOUTH AFRICA KBR, INC. 2006 STOCK AND INCENTIVE PLAN

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!